CN105669923B - 一种光敏抗菌型水凝胶及其制备方法 - Google Patents
一种光敏抗菌型水凝胶及其制备方法 Download PDFInfo
- Publication number
- CN105669923B CN105669923B CN201610225662.8A CN201610225662A CN105669923B CN 105669923 B CN105669923 B CN 105669923B CN 201610225662 A CN201610225662 A CN 201610225662A CN 105669923 B CN105669923 B CN 105669923B
- Authority
- CN
- China
- Prior art keywords
- aqueous solution
- montmorillonite
- sensitising agent
- tetra
- meso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 19
- 239000004964 aerogel Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 68
- 229910052901 montmorillonite Inorganic materials 0.000 claims abstract description 60
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 44
- 239000000017 hydrogel Substances 0.000 claims abstract description 42
- 230000001235 sensitizing effect Effects 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008367 deionised water Substances 0.000 claims abstract description 17
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 17
- 230000004048 modification Effects 0.000 claims abstract description 14
- 238000012986 modification Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 17
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 claims description 16
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 16
- 229920002554 vinyl polymer Polymers 0.000 claims description 14
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 12
- YIYFFLYGSHJWFF-UHFFFAOYSA-N [Zn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Zn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 YIYFFLYGSHJWFF-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 235000005074 zinc chloride Nutrition 0.000 claims description 6
- 239000011592 zinc chloride Substances 0.000 claims description 6
- 239000002689 soil Substances 0.000 claims description 5
- 229950004288 tosilate Drugs 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 2
- WVGVHKASKLKTLA-UHFFFAOYSA-N 1h-pyrrole;styrene Chemical compound C=1C=CNC=1.C=CC1=CC=CC=C1 WVGVHKASKLKTLA-UHFFFAOYSA-N 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 24
- 238000005286 illumination Methods 0.000 abstract description 13
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract description 8
- BIAWAXVRXKIUQB-UHFFFAOYSA-N 2-(2-phenylethenyl)pyridine Chemical class C=1C=CC=CC=1C=CC1=CC=CC=N1 BIAWAXVRXKIUQB-UHFFFAOYSA-N 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 241000233866 Fungi Species 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 231100000760 phototoxic Toxicity 0.000 abstract description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- YNJPEFIZCXXDIS-UHFFFAOYSA-N zinc;5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)porphyrin-22,24-diide Chemical compound [Zn+2].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 YNJPEFIZCXXDIS-UHFFFAOYSA-N 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 238000002428 photodynamic therapy Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 4
- 229910000679 solder Inorganic materials 0.000 description 4
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- 241000219095 Vitis Species 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011229 interlayer Substances 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000002990 phenothiazines Chemical class 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- WRLRISOTNFYPMU-UHFFFAOYSA-N [S].CC1=CC=CC=C1 Chemical compound [S].CC1=CC=CC=C1 WRLRISOTNFYPMU-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 cationic porphyrin Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000005837 radical ions Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/44—Polymerisation in the presence of compounding ingredients, e.g. plasticisers, dyestuffs, fillers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
- C08F2/50—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light with sensitising agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/34—Silicon-containing compounds
- C08K3/346—Clay
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K9/00—Use of pretreated ingredients
- C08K9/04—Ingredients treated with organic substances
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种光敏抗菌型水凝胶及其制备方法,该方法包括如下步骤:(1)将蒙脱土、光敏剂分别溶于去离子水,形成蒙脱土水溶液、光敏剂水溶液;(2)将蒙脱土水溶液与光敏剂水溶液混合,制得蒙脱土修饰的光敏剂水溶液;(3)将聚乙烯醇‑苯乙烯吡啶盐溶于去离子水,形成水溶液,并与步骤(2)制得的蒙脱土修饰的光敏剂水溶液混合;(4)最后,将步骤(3)制得的混合溶液置于紫外灯下照射,制得所述光敏抗菌型水凝胶。本发明水凝胶在可见光照射下能够产生光毒性的单线态氧,单线态氧能够高效的杀死病毒、细菌、真菌,且不会产生耐药性。
Description
技术领域
本发明涉及生物医用材料制备技术领域,尤其是涉及一种以蒙脱土、光敏剂、聚乙烯醇-苯乙烯吡啶盐为原料制得的光敏抗菌型水凝胶。
背景技术
水凝胶是以水为分散介质的凝胶,经过物理或化学交联而形成的具有三维空间网络结构的新型高分子材料之一,他不能在水中溶解,但能在水中溶胀,吸收大量的水分,有很强的蓄水能力,并具有良好的生物相容性和化学物理性质。
光动力疗法光动力疗法(Photodynamic Therapy,PDT)是近年来发展起来的一种新的物理化学治疗技术,其基本原理是光敏剂在特定波长光源的激发下进行能量跃迁,随后将能量转移给生物体内的氧,后者形成单线态氧、自由基或自由基离子等,它们作用于靶细胞,引起细胞死亡或凋亡。PDT以有效、可协同性、重复性和相对成本低等优点引起广泛关注。
亚甲基蓝是一种吩噻嗪类碱性染料,研究发现,细菌、酵母菌和原生生物等病原体对吩噻嗪类料具有易感性,因此,此类染料可应用于光动力抗微生物治疗;亚甲基蓝在医学领域的研究范围较为广泛,且历史久远,早在上个世纪三十年代就有关于亚甲基蓝对抗噬菌体和病毒感染的报道,亚甲基蓝除了具有疾病治疗作用外,还具有疾病诊断价值。
meso-四(N-甲基-4-吡啶)卟吩四氯化锌、meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)、meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐是三种种水溶性卟啉,属于第二代光敏剂。第二代光敏剂部分地克服了第一代光敏剂的组分复杂,对组织选择性和光动力损伤强度的稳定性很差的缺点。其主要优点为光敏期短,作用的光波波长较长,因而可增加作用深度,产生的单态氧也较多。
蒙脱土具有复层网状结构,由两层硅氧四面体夹一层铝氧八面体组成,四面体与八面体依靠共同的氧原子连结,在两层硅氧四面体中间充满着nH2O和可交换的阳离子,这种四面体和八面体的紧密堆积结构使其具有高度有序的晶格排列,每层的厚度约为1nm,具有很高的刚度,层间不宜滑动。由于蒙脱石的特殊结构,使它具有很大的表面积,比表面积可达750m2/g,因此蒙脱土对各种气体、液体、有机物质具有一定的吸附能力,最大吸附量可达5倍于它的重量。
发明内容
针对现有技术存在的上述问题,本申请人提供了一种光敏抗菌型水凝胶及其制备方法。本发明方法,首先用蒙脱土修饰光敏剂溶液,然后将其与聚乙烯醇-苯乙烯吡啶盐(PVA-SbQ)溶液混合,利用PVA-SbQ在365nm的紫外光照下能够进行自交联制得光敏抗菌型水凝胶;所得水凝胶在可见光照射下能够产生光毒性的单线态氧,单线态氧能够高效的杀死病毒、细菌、真菌,且不会产生耐药性。
本发明的技术方案如下:
一种光敏抗菌型水凝胶,所述水凝胶通过如下步骤制得:
(1)首先,在20~30℃下,将蒙脱土、光敏剂分别溶于去离子水,形成蒙脱土水溶液、光敏剂水溶液;
(2)然后,将蒙脱土水溶液与光敏剂水溶液混合,500rpm转速下,搅拌5~15min,制得蒙脱土修饰的光敏剂水溶液;
(3)再然后,将聚乙烯醇-苯乙烯吡啶盐溶于去离子水,形成水溶液,并与步骤(2)制得的蒙脱土修饰的光敏剂水溶液混合,500rpm转速下,搅拌3~15min;
(4)最后,将步骤(3)制得的混合溶液置于紫外灯下照射,制得所述光敏抗菌型水凝胶。
所述光敏剂为meso-四(N-甲基-4-吡啶)卟吩四氯化锌、meso-四(N-甲基-4-吡啶)卟啉锌、亚甲基蓝、meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐中的一种或多种。
所述蒙脱土水溶液、光敏剂水溶液的制备方法为:蒙脱土、光敏剂分别溶于去离子水后超声2~4次,每次10~40min。
所述步骤(1)中蒙脱土水溶液的质量浓度为0.001~1%;所述光敏剂水溶液的摩尔浓度为2μmol/L~10mmol/L。
所述步骤(2)中蒙脱土水溶液与光敏剂水溶液的体积比为1~5:1。
所述meso-四(N-甲基-4-吡啶)卟吩四氯化锌水溶液的浓度为2~500μmol/L;所述meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)水溶液的浓度为2~100μmol/L;所述亚甲基蓝水溶液的浓度为0.01~10mmol/L;所述meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐水溶液的浓度为50~1000μmol/L。
所述步骤(3)中聚乙烯醇-苯乙烯吡啶盐水溶液的质量浓度为30~90%;所述聚乙烯醇-苯乙烯吡啶盐水溶液与光敏剂溶液的体积比为1~3.5:1。
所述聚乙烯醇-苯乙烯吡啶盐中苯乙烯吡啶盐的含量为4.1mol%。
所述紫外灯照射的条件为:紫外光波长λ=365nm,照射强度为50~200mW/cm2,照射时间为0.5~5h。
本发明有益的技术效果在于:
(1)本发明利用水凝胶的三维网络空隙结构作为光敏剂的固体载体,可以显著提高单线态氧的寿命,同时水凝胶具备的良好的生物相容性使其具备广泛的生物应用前景。
(2)本发明采用紫外交联的方法制备光敏抗菌型水凝胶,采用PVA-SbQ(聚乙烯醇-苯乙烯吡啶盐)作为光交联剂,PVA-SbQ在365nm的紫外光照下会发生自聚合反应,这种光交联法方便快捷,具有工业化生产的前景。
(3)本发明采用亚甲基蓝、阳离子卟啉作为光敏剂,利用蒙脱土特有的层间阳离子交换能力修饰这些阳离子光敏剂,然后将其均匀的分散在水凝胶中可制得光敏抗菌型水凝胶;采用水溶性蒙脱土来吸附光敏剂,可达到光敏剂在水凝胶中均匀分布的效果。
(4)本发明利用了水凝胶和蒙脱土的透光性,有助于可见光穿透水凝胶激发光敏剂产生单线态氧;蒙脱土的存在可保证光敏剂在其层间不易溢出,有利于提高材料在作用环境中的稳定性。
附图说明
图1为PVA-SbQ在紫外光照射下发生自聚合反应的示意图。
图2为本发明对比例、实施例1、2、3制得水凝胶的抗菌性测试结果。
具体实施方式
下面结合附图和实施例,对本发明进行具体描述。
对比例
一种无光敏剂的水凝胶的制备方法如下:
(1)首先,在20℃下,将蒙脱土溶于去离子水,先搅拌20分钟,然后超声处理20分钟,重复上述过程一次,形成蒙脱土水溶液;所述蒙脱土水溶液的质量浓度为0.5%。
(2)然后,将聚乙烯醇-苯乙烯吡啶盐(PVA-SbQ)(苯乙烯吡啶盐的含量为4.1mol%)溶于去离子水,形成质量浓度为50%的水溶液,取其5mL并与步骤(1)制得的6mL蒙脱土水溶液混合,500rpm转速下,搅拌5min;
(3)最后,将步骤(2)制得的混合溶液置于紫外灯(λ=365nm)下照射2.5小时,照射强度为60mW/cm2,制得所述水凝胶。
将所得水凝胶进行冷冻干燥得到相应的气凝胶,将气凝胶裁剪成等面积小块进行抗菌评价(以金黄色葡萄球菌为例),设置三个平行组,分别为原菌液组、暗室组、光照组,三组互为对照,原菌液组不添加气凝胶,后两组用气凝胶吸附菌液后分别进行暗室、光照处理;然后取出菌液稀释6个梯度后将菌液转移到平板上,培养12h后查数菌落数。所得水凝胶的抗菌结果如图2所示。
由图2可以看出:不添加光敏剂制备得到的PVA-SbQ/蒙脱土水凝胶在光照条件下金黄色葡萄球菌的存活率为70.89%。
实施例1
一种光敏抗菌型水凝胶,所述水凝胶通过如下步骤制得:
(1)首先,在20℃下,将蒙脱土、亚甲基蓝分别溶于去离子水,先搅拌15分钟,然后超声处理10分钟,重复上述过程一次,形成蒙脱土水溶液、亚甲基蓝水溶液;所述蒙脱土水溶液的质量浓度为1%;所述亚甲基蓝水溶液的浓度为10000μmol/L。
(2)然后,将5mL蒙脱土水溶液与1mL亚甲基蓝水溶液混合,500rpm转速下,搅拌5min,制得蒙脱土修饰的亚甲基蓝水溶液;
(3)再然后,将聚乙烯醇-苯乙烯吡啶盐(PVA-SbQ)(苯乙烯吡啶盐的含量为4.1mol%)溶于去离子水,形成质量浓度为30%的水溶液,取其5mL并与步骤(2)制得的蒙脱土修饰的亚甲基蓝水溶液混合,500rpm转速下,搅拌4min;
(4)最后,将步骤(3)制得的混合溶液置于紫外灯(λ=365nm)下照射3小时,照射强度为75mW/cm2,制得所述光敏抗菌型水凝胶。
将所得水凝胶进行冷冻干燥得到相应的气凝胶,将气凝胶裁剪成等面积小块进行抗菌(以金黄色葡萄球菌为例)评价,设置三个平行组,分别为原菌液组、暗室组、光照组,三组互为对照,原菌液组不添加气凝胶,后两组用气凝胶吸附菌液后分别进行暗室、光照处理;然后取出菌液稀释6个梯度后将菌液转移到平板上,培养12h后查数菌落数。所得水凝胶的抗菌结果如图2所示。
由图2可以看出:不添加光敏剂制备得到的PVA-SbQ/蒙脱土水凝胶在光照条件下金黄色葡萄球菌的存活率为70.89%,本实施例制备得到的水凝胶在光照条件下金黄色葡萄球菌的存活率仅为0.05%,说明添加亚甲基蓝光敏剂后抗菌效果很明显。
实施例2
一种光敏抗菌型水凝胶,所述水凝胶通过如下步骤制得:
(1)首先,在30℃下,将蒙脱土、meso-四(N-甲基-4-吡啶)卟吩四氯化锌分别溶于去离子水,先搅拌20分钟,然后超声处理20分钟,重复上述过程一次,形成蒙脱土水溶液、meso-四(N-甲基-4-吡啶)卟吩四氯化锌水溶液;所述蒙脱土水溶液的质量浓度为0.1%;所述meso-四(N-甲基-4-吡啶)卟吩四氯化锌水溶液的浓度为100μmol/L。
(2)然后,将5mL蒙脱土水溶液与1mLmeso-四(N-甲基-4-吡啶)卟吩四氯化锌水溶液混合,500rpm转速下,搅拌6min,制得蒙脱土修饰的meso-四(N-甲基-4-吡啶)卟吩四氯化锌水溶液;
(3)再然后,将聚乙烯醇-苯乙烯吡啶盐(PVA-SbQ)(苯乙烯吡啶盐的含量为4.1mol%)溶于去离子水,形成质量浓度为50%的水溶液,取其5mL并与步骤(2)制得的蒙脱土修饰的meso-四(N-甲基-4-吡啶)卟吩四氯化锌水溶液混合,500rpm转速下,搅拌5min;
(4)最后,将步骤(3)制得的混合溶液置于紫外灯(λ=365nm)下照射2h,照射强度为100mW/cm2,制得所述光敏抗菌型水凝胶。
将所得水凝胶进行冷冻干燥得到相应的气凝胶,将气凝胶裁剪成等面积小块进行抗菌(以金黄色葡萄球菌为例)评价,设置三个平行组,分别为原菌液组、暗室组、光照组,三组互为对照,原菌液组不添加气凝胶,后两组用气凝胶吸附菌液后分别进行暗室、光照处理;然后取出菌液稀释6个梯度后将菌液转移到平板上,培养12h后查数菌落数。所得水凝胶的抗菌结果如图2所示。
由图2可以看出:不添加光敏剂制备得到的PVA-SbQ/蒙脱土水凝胶在光照条件下金黄色葡萄球菌的存活率为70.89%,本实施例制备得到的水凝胶在光照条件下金黄色葡萄球菌的存活率仅为0.03%,说明添加meso-四(N-甲基-4-吡啶)卟吩四氯化锌光敏剂后抗菌效果很明显。
实施例3
一种光敏抗菌型水凝胶,所述水凝胶通过如下步骤制得:
(1)首先,在20℃下,将蒙脱土、meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐分别溶于去离子水,先搅拌25分钟,然后超声处理30分钟,重复上述过程两次,形成蒙脱土水溶液、meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐水溶液;所述蒙脱土水溶液的质量浓度为0.5%;所述meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐水溶液的浓度为500μmol/L。
(2)然后,将5mL蒙脱土水溶液与1mL meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐水溶液混合,500rpm转速下,搅拌8min,制得蒙脱土修饰的meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐水溶液;
(3)再然后,将聚乙烯醇-苯乙烯吡啶盐(PVA-SbQ)(苯乙烯吡啶盐的含量为4.1mol%)溶于去离子水,形成质量浓度为70%的水溶液,取其5mL并与步骤(2)制得的蒙脱土修饰的meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐水溶液混合,500rpm转速下,搅拌4min;
(4)最后,将步骤(3)制得的混合溶液置于紫外灯(λ=365nm)下照射1.5h,照射强度为200mW/cm2,制得所述光敏抗菌型水凝胶。
将所得水凝胶进行冷冻干燥得到相应的气凝胶,将气凝胶裁剪成等面积小块进行抗菌(以金黄色葡萄球菌为例)评价,设置三个平行组,分别为原菌液组、暗室组、光照组,三组互为对照,原菌液组不添加气凝胶,后两组用气凝胶吸附菌液后分别进行暗室、光照处理;然后取出菌液稀释6个梯度后将菌液转移到平板上,培养12h后查数菌落数。所得水凝胶的抗菌结果如图2所示。
由图2可以看出:不添加光敏剂制备得到的PVA-SbQ/蒙脱土水凝胶在光照条件下金黄色葡萄球菌的存活率为70.89%,本实施例制备得到的水凝胶在光照条件下金黄色葡萄球菌的存活率仅为0.15%,说明添加meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐光敏剂后抗菌效果明显。
实施例4
一种光敏抗菌型水凝胶,所述水凝胶通过如下步骤制得:
(1)首先,在30℃下,将蒙脱土、meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)分别溶于去离子水,先搅拌30分钟,然后超声处理30分钟,重复上述过程两次,形成蒙脱土水溶液、meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)水溶液;所述蒙脱土水溶液的质量浓度为0.01%;所述meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)水溶液的浓度为50μmol/L。
(2)然后,将5mL蒙脱土水溶液与1mL meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)水溶液混合,500rpm转速下,搅拌10min,制得蒙脱土修饰的meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)水溶液;
(3)再然后,将聚乙烯醇-苯乙烯吡啶盐(PVA-SbQ)(苯乙烯吡啶盐的含量为4.1mol%)溶于去离子水,形成质量浓度为80%的水溶液,取其5mL并与步骤(2)制得的蒙脱土修饰的meso-四(N-甲基-4-吡啶)卟啉锌(Zn-TMPyP)水溶液混合,500rpm转速下,搅拌5min;
(4)最后,将步骤(3)制得的混合溶液置于紫外灯(λ=365nm)下照射3h,照射强度为50mW/cm2,制得所述光敏抗菌型水凝胶。
Claims (9)
1.一种光敏抗菌型水凝胶,其特征在于所述水凝胶通过如下步骤制得:
(1)首先,在20~30℃下,将蒙脱土、光敏剂分别溶于去离子水,形成蒙脱土水溶液、光敏剂水溶液;
(2)然后,将蒙脱土水溶液与光敏剂水溶液混合,500rpm转速下,搅拌5~15min,制得蒙脱土修饰的光敏剂水溶液;
(3)再然后,将聚乙烯醇-苯乙烯吡啶盐溶于去离子水,形成水溶液,并与步骤(2)制得的蒙脱土修饰的光敏剂水溶液混合,500rpm转速下,搅拌3~15min;
(4)最后,将步骤(3)制得的混合溶液置于紫外灯下照射,制得所述光敏抗菌型水凝胶。
2.根据权利要求1所述的水凝胶,其特征在于所述光敏剂为meso-四(N-甲基-4-吡啶)卟吩四氯化锌、meso-四(N-甲基-4-吡啶)卟啉锌、亚甲基蓝、meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐中的一种或多种。
3.根据权利要求1所述的水凝胶,其特征在于所述蒙脱土水溶液、光敏剂水溶液的制备方法为:蒙脱土、光敏剂分别溶于去离子水后超声2~4次,每次10~40min。
4.根据权利要求1所述的水凝胶,其特征在于所述步骤(1)中蒙脱土水溶液的质量浓度为0.001~1%;所述光敏剂水溶液的摩尔浓度为2μmol/L~10mmol/L。
5.根据权利要求1所述的水凝胶,其特征在于所述步骤(2)中蒙脱土水溶液与光敏剂水溶液的体积比为1~5:1。
6.根据权利要求2所述的水凝胶,其特征在于所述meso-四(N-甲基-4-吡啶)卟吩四氯化锌水溶液的浓度为2~500μmol/L;所述meso-四(N-甲基-4-吡啶)卟啉锌水溶液的浓度为2~100μmol/L;所述亚甲基蓝水溶液的浓度为0.01~10mmol/L;所述meso-四(1-甲基吡啶嗡-4-基)卟吩对甲苯磺酸盐水溶液的浓度为50~1000μmol/L。
7.根据权利要求1所述的水凝胶,其特征在于所述步骤(3)中聚乙烯醇-苯乙烯吡啶盐水溶液的质量浓度为30~90%;所述聚乙烯醇-苯乙烯吡啶盐水溶液与蒙脱土修饰的光敏剂水溶液的体积比为1~3.5:1。
8.根据权利要求1所述的水凝胶,其特征在于所述聚乙烯醇-苯乙烯吡啶盐中苯乙烯吡啶盐的含量为4.1mol%。
9.根据权利要求1所述的水凝胶,其特征在于所述步骤(4)中紫外灯照射的条件为:紫外光波长λ=365nm,照射强度为50~200mW/cm2,照射时间为0.5~5h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610225662.8A CN105669923B (zh) | 2016-04-12 | 2016-04-12 | 一种光敏抗菌型水凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610225662.8A CN105669923B (zh) | 2016-04-12 | 2016-04-12 | 一种光敏抗菌型水凝胶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105669923A CN105669923A (zh) | 2016-06-15 |
CN105669923B true CN105669923B (zh) | 2017-11-10 |
Family
ID=56310216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610225662.8A Active CN105669923B (zh) | 2016-04-12 | 2016-04-12 | 一种光敏抗菌型水凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105669923B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111440349B (zh) * | 2020-06-01 | 2022-05-27 | 中国石油大学(华东) | 一种海藻酸钠抗菌敷料的制备方法 |
CN111718435B (zh) * | 2020-06-17 | 2021-12-28 | 西北大学 | 一种抗菌高分子聚乙烯醇材料及方法和应用 |
CN113787786B (zh) * | 2021-08-09 | 2022-05-20 | 江南大学 | 一种夜光储能长效光动力抗菌型面料及其制备方法 |
CN113694243B (zh) * | 2021-08-20 | 2022-05-13 | 中国地质大学(武汉) | 一种光敏剂/粘土复合材料及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209360A1 (en) * | 2003-04-18 | 2004-10-21 | Keith Steven C. | PVA-based polymer coating for cell culture |
CN101914225A (zh) * | 2010-08-05 | 2010-12-15 | 江南大学 | 一种大分子光交联剂制备透明质酸凝胶的方法 |
CN104262534B (zh) * | 2014-09-10 | 2016-08-10 | 江南大学 | 一种蒙脱土复合阳离子水凝胶及其制备方法 |
-
2016
- 2016-04-12 CN CN201610225662.8A patent/CN105669923B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105669923A (zh) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105669923B (zh) | 一种光敏抗菌型水凝胶及其制备方法 | |
Zeng et al. | Enhancing triplet–triplet annihilation upconversion: from molecular design to present applications | |
Wang et al. | Highly efficient photosensitizers with far‐red/near‐infrared aggregation‐induced emission for in vitro and in vivo cancer theranostics | |
Zheng et al. | Nanoscale mixed-component metal–organic frameworks with photosensitizer spatial-arrangement-dependent photochemistry for multimodal-imaging-guided photothermal therapy | |
Amaly et al. | Synergistic adsorption‑photocatalytic degradation of tetracycline by microcrystalline cellulose composite aerogel dopped with montmorillonite hosted methylene blue | |
Gehring et al. | Sunlight-triggered nanoparticle synergy: teamwork of reactive oxygen species and nitric oxide released from mesoporous organosilica with advanced antibacterial activity | |
CN108864106B (zh) | 近红外二区有机小分子荧光探针的制备与应用 | |
Zhao et al. | Aggregate materials beyond AIEgens | |
CN111440349B (zh) | 一种海藻酸钠抗菌敷料的制备方法 | |
CN111298141A (zh) | 一种基于铁和多巴胺配位的纳米颗粒光热转换材料及其制备方法和应用 | |
CN108671231A (zh) | 一种用于肿瘤光热增效治疗和超声成像的多功能纳米载体及制备方法 | |
Ahmed et al. | Tetracycline encapsulated in Au nanoparticle-decorated ZnO nanohybrids for enhanced antibacterial activity | |
CN107469079A (zh) | 一种t1‑mri成像引导下的光动治疗剂制备方法 | |
Wang et al. | Acrylate-functionalized porphyrin-covalent organic framework for bacterial-targeted and reaction-enhanced synergistic phototherapy/chemotherapy toward sterilization and wound healing | |
Lu et al. | A nano-BODIPY encapsulated zeolitic imidazolate framework as photoresponsive integrating antibacterial agent | |
Xu et al. | Defective transition metal hydroxide-based nanoagents with hypoxia relief for photothermal-enhanced photodynamic therapy | |
CN113018436B (zh) | 一种抗菌金属离子-酞菁/聚多巴胺纳米球及其制备方法 | |
Boase | Shining a light on bioorthogonal photochemistry for polymer science | |
Su et al. | Photothermal-driven disassembly of naphthalocyanine nano-photosensitizers for photothermal and photodynamic therapy | |
CN106035351B (zh) | 一种负载光敏剂的聚合物胶束的制备方法及该胶束在浮游细菌、细菌生物被膜杀灭中的应用 | |
CN103784978A (zh) | 一种蛋白-染料复合物及其应用 | |
KR101398734B1 (ko) | 교반법을 이용한 광기능성 고분자 소재의 제조방법 | |
CN112409365A (zh) | 3-磺酸基丙烷巯基修饰酞菁及其制备方法与在制药领域的应用 | |
Ndlovu et al. | Porphyrins developed for photoinactivation of microbes in wastewater | |
CN115232271B (zh) | 一种光热/光动力/化学杀菌一体的卟啉基共价有机骨架材料及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |